A decades-old glaucoma drug tossed aside by Pfizer gets a new life at a small biotech
Months ago, Pfizer made a grim announcement that it would stop manufacturing phospholine iodide, its decades-old “miracle drug” for a rare form of glaucoma. The pharma said its inventory would run dry by May 2021, leaving some patients with few options short of surgery.
But after snagging the rights and the rest of Pfizer’s supply, a small New York biotech is looking to give phospholine iodide new life.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.